Equities research analysts expect that Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) will announce sales of $481.81 million for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Jazz Pharmaceuticals’ earnings. The lowest sales estimate is $475.55 million and the highest is $485.49 million. Jazz Pharmaceuticals reported sales of $411.86 million during the same quarter last year, which indicates a positive year over year growth rate of 17%. The company is scheduled to report its next earnings report on Tuesday, November 6th.

On average, analysts expect that Jazz Pharmaceuticals will report full-year sales of $1.92 billion for the current year, with estimates ranging from $1.90 billion to $1.93 billion. For the next year, analysts forecast that the firm will report sales of $2.16 billion, with estimates ranging from $2.07 billion to $2.24 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.23 by $0.26. The business had revenue of $500.48 million during the quarter, compared to analysts’ expectations of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%.

JAZZ has been the subject of a number of research reports. Citigroup raised their price target on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a “buy” rating in a report on Tuesday, July 10th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Sunday, July 8th. BidaskClub cut shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 28th. B. Riley raised their price target on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the stock a “buy” rating in a report on Tuesday, June 26th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $213.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, August 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company. Jazz Pharmaceuticals currently has an average rating of “Buy” and an average target price of $192.61.

In other news, CEO Bruce C. Cozadd sold 1,600 shares of Jazz Pharmaceuticals stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $173.90, for a total transaction of $278,240.00. Following the completion of the transaction, the chief executive officer now directly owns 282,515 shares in the company, valued at $49,129,358.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rick E. Winningham sold 16,639 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $176.18, for a total transaction of $2,931,459.02. Following the transaction, the director now owns 15,594 shares of the company’s stock, valued at $2,747,350.92. The disclosure for this sale can be found here. Insiders have sold 34,978 shares of company stock valued at $6,030,128 over the last quarter. Corporate insiders own 3.90% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. bought a new stake in Jazz Pharmaceuticals in the first quarter worth about $192,000. Dimensional Fund Advisors LP raised its position in shares of Jazz Pharmaceuticals by 14.7% in the first quarter. Dimensional Fund Advisors LP now owns 291,850 shares of the specialty pharmaceutical company’s stock valued at $44,066,000 after purchasing an additional 37,486 shares during the period. Russell Investments Group Ltd. raised its position in shares of Jazz Pharmaceuticals by 113.0% in the first quarter. Russell Investments Group Ltd. now owns 32,015 shares of the specialty pharmaceutical company’s stock valued at $4,803,000 after purchasing an additional 16,983 shares during the period. Sei Investments Co. raised its position in shares of Jazz Pharmaceuticals by 75.9% in the first quarter. Sei Investments Co. now owns 9,698 shares of the specialty pharmaceutical company’s stock valued at $1,464,000 after purchasing an additional 4,185 shares during the period. Finally, Stifel Financial Corp raised its position in shares of Jazz Pharmaceuticals by 13.7% in the first quarter. Stifel Financial Corp now owns 20,861 shares of the specialty pharmaceutical company’s stock valued at $3,163,000 after purchasing an additional 2,518 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

NASDAQ:JAZZ traded down $0.01 during trading hours on Wednesday, reaching $155.99. The company had a trading volume of 417,521 shares, compared to its average volume of 435,077. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $9.42 billion, a price-to-earnings ratio of 16.32, a PEG ratio of 0.85 and a beta of 1.04. Jazz Pharmaceuticals has a twelve month low of $128.58 and a twelve month high of $184.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Further Reading: Day Trading

Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.